Théa Open Innovation and CURACLE, a Korea-based biopharmaceutical company, have entered into an exclusive license and collaboration agreement for the development and commercialization of Curacle’s CU06-RE, that has the potential to become the first orally administered treatment for diabetic macular edema and wet age-related macular degeneration.
Théa and Kiora Pharmaceuticals sign a new partnership
1 February 2024